{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T22:02:56Z","timestamp":1790805776392,"version":"4.1.0"},"reference-count":79,"publisher":"Elsevier BV","issue":"10","license":[{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/100000897","name":"Cystic Fibrosis Foundation","doi-asserted-by":"publisher","award":["Envision: Emerging Leaders in CF Endocrinology grant"],"award-info":[{"award-number":["Envision: Emerging Leaders in CF Endocrinology grant"]}],"id":[{"id":"10.13039\/100000897","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["aacejournalendocrinepractice.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Endocrine Practice"],"published-print":{"date-parts":[[2026,10]]},"DOI":"10.1016\/j.eprac.2026.05.038","type":"journal-article","created":{"date-parts":[[2026,6,10]],"date-time":"2026-06-10T07:34:03Z","timestamp":1781076843000},"page":"1583-1589","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Updates in Cystic Fibrosis\u2013Related Diabetes (CFRD)"],"prefix":"10.1016","volume":"32","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8159-0625","authenticated-orcid":false,"given":"Henry","family":"Zelada","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katie L.","family":"Kaput","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shauna","family":"Runchey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Trang N.","family":"Le","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.eprac.2026.05.038_bib1","doi-asserted-by":"crossref","first-page":"R35","DOI":"10.1530\/JOE-18-0468","article-title":"Survival in a bad neighborhood: pancreatic islets in cystic fibrosis","volume":"241","author":"Norris","year":"2019","journal-title":"J Endocrinol"},{"key":"10.1016\/j.eprac.2026.05.038_bib2","article-title":"CFRD caused by islet loss and dysfunction","volume":"3","author":"Tao","year":"2018","journal-title":"JCI Insight"},{"key":"10.1016\/j.eprac.2026.05.038_bib3","article-title":"Cystic fibrosis\u2013related diabetes: pathophysiology, screening and management","volume":"162","author":"Blackman","year":"2020","journal-title":"Diabetes Res Clin Pract"},{"issue":"4","key":"10.1016\/j.eprac.2026.05.038_bib4","doi-asserted-by":"crossref","first-page":"823","DOI":"10.2337\/dc17-1387","article-title":"Islet interleukin-1\u03b2 immunoreactivity is an early feature of cystic fibrosis that may contribute to \u03b2-cell failure","volume":"41","author":"Hull","year":"2018","journal-title":"Diabetes Care"},{"key":"10.1016\/j.eprac.2026.05.038_bib5","doi-asserted-by":"crossref","DOI":"10.1155\/pedi\/5539725","article-title":"From pathophysiology to treatment: contemporary approaches to CFRD in the pediatric and adolescent population","volume":"2026","author":"Vuralli","year":"2026","journal-title":"Pediatr Diabetes"},{"issue":"3","key":"10.1016\/j.eprac.2026.05.038_bib6","first-page":"927","article-title":"Early \u03b2-cell area reduction in children with cystic fibrosis","volume":"63","author":"Bogdani","year":"2014","journal-title":"Diabetes"},{"issue":"3","key":"10.1016\/j.eprac.2026.05.038_bib7","first-page":"594","article-title":"Mechanisms of \u03b2-cell dysfunction in cystic fibrosis","volume":"67","author":"Hart","year":"2018","journal-title":"Diabetes"},{"issue":"1","key":"10.1016\/j.eprac.2026.05.038_bib8","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1016\/j.jcf.2022.07.014","article-title":"Insulinogenic index and early-phase insulin secretion predict increased risk of worsening glucose tolerance and of cystic fibrosis-related diabetes","volume":"22","author":"Potter","year":"2023","journal-title":"J Cyst Fibros"},{"key":"10.1016\/j.eprac.2026.05.038_bib9","doi-asserted-by":"crossref","DOI":"10.3389\/fendo.2021.702823","article-title":"The potential causes of cystic fibrosis-related diabetes","volume":"12","author":"Coderre","year":"2021","journal-title":"Front Endocrinol (Lausanne)"},{"issue":"5","key":"10.1016\/j.eprac.2026.05.038_bib10","doi-asserted-by":"crossref","first-page":"1366","DOI":"10.1210\/clinem\/dgz209","article-title":"In situ analysis reveals that CFTR is expressed in only a small minority of \u03b2-cells in normal adult human pancreas but is present in ductal and non\u2013\u03b2 endocrine cells","volume":"105","author":"White","year":"2020","journal-title":"J Clin Endocrinol Metab"},{"issue":"1","key":"10.1016\/j.eprac.2026.05.038_bib11","first-page":"89","article-title":"Quantitative morphologic study of the endocrine pancreas in cystic fibrosis","volume":"122","author":"Abdul-Karim","year":"1986","journal-title":"Am J Pathol"},{"key":"10.1016\/j.eprac.2026.05.038_bib12","article-title":"CFTR regulates glucagon secretion through modulation of KATP channels in \u03b1-cells","volume":"7","author":"Edlund","year":"2017","journal-title":"Sci Rep"},{"issue":"2","key":"10.1016\/j.eprac.2026.05.038_bib13","first-page":"179","article-title":"Islet changes in cystic fibrosis: increased \u03b1-cell area and disturbed architecture","volume":"415","author":"Lohr","year":"1989","journal-title":"Virchows Arch A Pathol Anat Histopathol"},{"issue":"7","key":"10.1016\/j.eprac.2026.05.038_bib14","doi-asserted-by":"crossref","first-page":"1406","DOI":"10.2337\/dc17-2419","article-title":"Hemoglobin A1c accurately predicts continuous glucose monitoring\u2013derived average glucose in youth and young adults with cystic fibrosis","volume":"41","author":"Chan","year":"2018","journal-title":"Diabetes Care"},{"key":"10.1016\/j.eprac.2026.05.038_bib15","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1016\/j.jcjd.2024.09.001","article-title":"Cystic fibrosis\u2013related diabetes: a First Canadian Clinical Practice Guideline","volume":"49","author":"Coriati","year":"2025","journal-title":"Can J Diabetes"},{"issue":"1","key":"10.1016\/j.eprac.2026.05.038_bib16","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1016\/j.jcjd.2018.04.008","article-title":"Cystic fibrosis-related diabetes screening in adults: a gap analysis and evaluation of accuracy of glycated hemoglobin levels","volume":"43","author":"Gilmour","year":"2019","journal-title":"Can J Diabetes"},{"key":"10.1016\/j.eprac.2026.05.038_bib17","first-page":"3","article-title":"Cystic fibrosis-related diabetes: clinical approach and knowledge gaps","volume":"46","author":"Prentice","year":"2023","journal-title":"Paediatr Respir Rev"},{"issue":"7","key":"10.1016\/j.eprac.2026.05.038_bib18","doi-asserted-by":"crossref","first-page":"1173","DOI":"10.1111\/pedi.12700","article-title":"\u03b2-Cell secretory defects are present in pancreatic insufficient cystic fibrosis with 1-hour oral glucose tolerance test glucose \u2265155 mg\/dL","volume":"19","author":"Nyirjesy","year":"2018","journal-title":"Pediatr Diabetes"},{"issue":"8","key":"10.1016\/j.eprac.2026.05.038_bib19","doi-asserted-by":"crossref","first-page":"1650","DOI":"10.2337\/dc08-0225","article-title":"One-hour plasma glucose concentration and the metabolic syndrome identify subjects at high risk for future type 2 diabetes","volume":"31","author":"Abdul-Ghani","year":"2008","journal-title":"Diabetes Care"},{"issue":"5","key":"10.1016\/j.eprac.2026.05.038_bib20","doi-asserted-by":"crossref","first-page":"696","DOI":"10.1016\/j.jcf.2020.01.003","article-title":"Abnormal glucose tolerance and the 50-gram glucose challenge test in Cystic fibrosis","volume":"19","author":"Sheikh","year":"2020","journal-title":"J Cyst Fibros"},{"issue":"4","key":"10.1016\/j.eprac.2026.05.038_bib21","doi-asserted-by":"crossref","first-page":"e1444","DOI":"10.1210\/clinem\/dgab857","article-title":"Continuous glucose monitoring and HbA1c in cystic fibrosis: clinical correlations and implications for CFRD diagnosis","volume":"107","author":"Scully","year":"2022","journal-title":"J Clin Endocrinol Metab"},{"issue":"11","key":"10.1016\/j.eprac.2026.05.038_bib22","doi-asserted-by":"crossref","first-page":"3978","DOI":"10.3390\/jcm14113978","article-title":"Cystic Fibrosis transmembrane conductance regulator modulators in cystic fibrosis: a review of registry-based evidence","volume":"14","author":"Salvatore","year":"2025","journal-title":"J Clin Med"},{"issue":"10408","key":"10.1016\/j.eprac.2026.05.038_bib23","doi-asserted-by":"crossref","first-page":"1171","DOI":"10.1016\/S0140-6736(23)01609-4","article-title":"CFTR modulator therapy: transforming the landscape of clinical care in cystic fibrosis","volume":"402","author":"Taylor-Cousar","year":"2023","journal-title":"Lancet"},{"key":"10.1016\/j.eprac.2026.05.038_bib24","doi-asserted-by":"crossref","DOI":"10.3389\/fped.2022.852551","article-title":"Short-term effects of Elexacaftor\/Tezacaftor\/Ivacaftor combination on glucose tolerance in young people with cystic Fibrosis\u2014an observational pilot study","volume":"10","author":"Korten","year":"2022","journal-title":"Front Pediatr"},{"key":"10.1016\/j.eprac.2026.05.038_bib25","article-title":"Decreased insulin dose-adjusted hemoglobin A1c in adults with cystic fibrosis-related diabetes treated with elexacaftor-tezacaftor-ivacaftor","volume":"41","author":"Burnet","year":"2025","journal-title":"J Clin Transl Endocrinol"},{"key":"10.1016\/j.eprac.2026.05.038_bib26","article-title":"Combined CFTR modulator therapies are linked with anabolic benefits and insulin-sparing in cystic fibrosis-related diabetes","volume":"33","author":"Lurquin","year":"2023","journal-title":"J Clin Transl Endocrinol"},{"issue":"9","key":"10.1016\/j.eprac.2026.05.038_bib27","doi-asserted-by":"crossref","first-page":"2674","DOI":"10.1210\/clinem\/dgae857","article-title":"Glycemia and insulin secretion in cystic fibrosis 2 years after elexacaftor\/tezacaftor\/ivacaftor: promise-endo","volume":"110","author":"Chan","year":"2025","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.eprac.2026.05.038_bib29","first-page":"67","article-title":"Nutritional assessment in adults with cystic fibrosis","author":"Bellini","year":"2019","journal-title":"Nutrition"},{"issue":"6","key":"10.1016\/j.eprac.2026.05.038_bib30","first-page":"437","article-title":"Pathogenesis of malnutrition in cystic fibrosis, and its treatment","volume":"19","author":"Prentice","year":"2000","journal-title":"Clin Nutr"},{"issue":"1","key":"10.1016\/j.eprac.2026.05.038_bib31","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1038\/s41390-020-0860-3","article-title":"Association between faecal pH and fat absorption in children with cystic fibrosis on a controlled diet and enzyme supplements dose","volume":"89","author":"Calvo-Lerma","year":"2021","journal-title":"Pediatr Res"},{"issue":"5","key":"10.1016\/j.eprac.2026.05.038_bib32","doi-asserted-by":"crossref","first-page":"832","DOI":"10.1016\/j.jada.2008.02.020","article-title":"Evidence-based practice recommendations for nutrition-related management of children and adults with cystic fibrosis and pancreatic insufficiency: results of a systematic review","volume":"108","author":"Stallings","year":"2008","journal-title":"J Am Diet Assoc"},{"issue":"5","key":"10.1016\/j.eprac.2026.05.038_bib33","first-page":"697","article-title":"Obesity in Cystic fibrosis: prevalence, trends and associated factors data from the US cystic fibrosis foundation patient registry","volume":"21","author":"Sharifi","year":"2022","journal-title":"J Cyst Fibros"},{"issue":"2","key":"10.1016\/j.eprac.2026.05.038_bib34","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1249\/MSS.0000000000001104","article-title":"Combined exercise training improves glycemic control in adults with cystic fibrosis","volume":"49","author":"Boudreau","year":"2017","journal-title":"Med Sci Sports Exerc"},{"issue":"1","key":"10.1016\/j.eprac.2026.05.038_bib35","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1016\/j.jshs.2022.10.003","article-title":"Exercise sustains the hallmarks of health","volume":"12","author":"Qiu","year":"2023","journal-title":"J Sport Health Sci"},{"issue":"1","key":"10.1016\/j.eprac.2026.05.038_bib36","doi-asserted-by":"crossref","first-page":"42","DOI":"10.3138\/ptc.2016-75","article-title":"Relationship between physical activity and fatigue in adults with cystic fibrosis","volume":"70","author":"Orava","year":"2018","journal-title":"Physiother Can"},{"issue":"8","key":"10.1016\/j.eprac.2026.05.038_bib37","first-page":"871","article-title":"Diabetes mellitus in cystic fibrosis: effect of insulin therapy on lung function and infections","volume":"83","author":"Little","year":"1994","journal-title":"Acta Paediatr"},{"issue":"12","key":"10.1016\/j.eprac.2026.05.038_bib38","doi-asserted-by":"crossref","first-page":"2697","DOI":"10.2337\/dc10-1768","article-title":"Clinical care guidelines for cystic fibrosis-related diabetes: a position statement of the American Diabetes Association and a clinical practice guideline of the Cystic Fibrosis Foundation, endorsed by the Pediatric Endocrine Society","volume":"33","author":"Moran","year":"2010","journal-title":"Diabetes Care"},{"issue":"8","key":"10.1016\/j.eprac.2026.05.038_bib39","doi-asserted-by":"crossref","first-page":"1212","DOI":"10.1111\/pedi.13453","article-title":"ISPAD Clinical Practice Consensus Guidelines 2022: management of cystic fibrosis-related diabetes in children and adolescents","volume":"23","author":"Ode","year":"2022","journal-title":"Pediatr Diabetes"},{"key":"10.1016\/j.eprac.2026.05.038_bib40","doi-asserted-by":"crossref","DOI":"10.3389\/fendo.2024.1347141","article-title":"Efficacy of advanced hybrid closed loop systems in cystic fibrosis related diabetes: a pilot study","volume":"15","author":"Bassi","year":"2024","journal-title":"Front Endocrinol"},{"issue":"1","key":"10.1016\/j.eprac.2026.05.038_bib41","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1016\/j.jcf.2022.07.013","article-title":"Continuous glucose monitoring versus self-monitoring of blood glucose in the management of cystic fibrosis related diabetes: a systematic review and meta-analysis","volume":"22","author":"Kumar","year":"2023","journal-title":"J Cyst Fibros"},{"issue":"Suppl 2","key":"10.1016\/j.eprac.2026.05.038_bib42","doi-asserted-by":"crossref","first-page":"S10","DOI":"10.1016\/j.jcf.2019.08.003","article-title":"Cystic fibrosis-related diabetes: medical management","volume":"18","author":"Ode","year":"2019","journal-title":"J Cyst Fibros"},{"issue":"Suppl 2","key":"10.1016\/j.eprac.2026.05.038_bib43","doi-asserted-by":"crossref","first-page":"S19","DOI":"10.1016\/j.jcf.2019.08.004","article-title":"Hypoglycemia in cystic fibrosis: prevalence, impact and treatment","volume":"18","author":"Moheet","year":"2019","journal-title":"J Cyst Fibros"},{"issue":"10","key":"10.1016\/j.eprac.2026.05.038_bib44","doi-asserted-by":"crossref","first-page":"3179","DOI":"10.1210\/clinem\/dgaa448","article-title":"Hypoglycemia and islet dysfunction following oral glucose tolerance testing in pancreatic-insufficient cystic fibrosis","volume":"105","author":"Kilberg","year":"2020","journal-title":"J Clin Endocrinol Metab"},{"issue":"11","key":"10.1016\/j.eprac.2026.05.038_bib45","doi-asserted-by":"crossref","first-page":"886","DOI":"10.1016\/S2213-8587(15)00280-6","article-title":"Efficacy, safety, and patient acceptability of Technosphere inhaled insulin for people with diabetes: a systematic review and meta-analysis","volume":"3","author":"Pittas","year":"2015","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"2","key":"10.1016\/j.eprac.2026.05.038_bib46","doi-asserted-by":"crossref","first-page":"452","DOI":"10.1177\/19322968231204584","article-title":"The role of ultra-rapid-acting insulin analogs in diabetes: an expert consensus","volume":"19","author":"Giorgino","year":"2025","journal-title":"J Diabetes Sci Technol"},{"issue":"4","key":"10.1016\/j.eprac.2026.05.038_bib47","doi-asserted-by":"crossref","first-page":"318","DOI":"10.1016\/j.jcf.2013.02.008","article-title":"Update on cystic fibrosis-related diabetes","volume":"12","author":"Kelly","year":"2013","journal-title":"J Cyst Fibros"},{"issue":"Supplement_1","key":"10.1016\/j.eprac.2026.05.038_bib48","doi-asserted-by":"crossref","first-page":"S181","DOI":"10.2337\/dc25-S009","article-title":"Pharmacologic approaches to glycemic treatment: standards of care in Diabetes\u20142025","volume":"48","author":"Elsayed","year":"2025","journal-title":"Diabetes Care"},{"issue":"3","key":"10.1016\/j.eprac.2026.05.038_bib49","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1016\/j.jcf.2008.12.001","article-title":"Use of the insulin pump in treat cystic fibrosis related diabetes","volume":"8","author":"Hardin","year":"2009","journal-title":"J Cyst Fibros"},{"issue":"11","key":"10.1016\/j.eprac.2026.05.038_bib50","doi-asserted-by":"crossref","first-page":"1483","DOI":"10.1007\/s00592-024-02329-7","article-title":"Offlabel use of Medtronic MiniMed 780G in the management of cystic fibrosis related diabetes in people requiring insulin total daily doses below 8 units: encouraging data from our population","volume":"61","author":"Grancini","year":"2024","journal-title":"Acta Diabetol"},{"issue":"10","key":"10.1016\/j.eprac.2026.05.038_bib51","doi-asserted-by":"crossref","first-page":"1783","DOI":"10.2337\/dc09-0585","article-title":"Insulin therapy to improve BMI in CFRD without fasting hyperglycemia: CFRDT trial","volume":"32","author":"Moran","year":"2009","journal-title":"Diabetes Care"},{"key":"10.1016\/j.eprac.2026.05.038_bib52","doi-asserted-by":"crossref","DOI":"10.3389\/fendo.2024.1347141","article-title":"Efficacy of advanced hybrid closed loop systemsin cystic fibrosis related diabetes: a pilot study","author":"Bassi","year":"2024","journal-title":"Front Endocrinol"},{"issue":"6","key":"10.1016\/j.eprac.2026.05.038_bib53","doi-asserted-by":"crossref","DOI":"10.1089\/dia.2021.0354","article-title":"The effect of control IQ hybrid closed loop technology on glycemic control in adolescents and adults with cystic fibrosis-related diabetes","volume":"24","author":"Scully","year":"2022","journal-title":"Diabetes Technology Ther"},{"key":"10.1016\/j.eprac.2026.05.038_bib54","doi-asserted-by":"crossref","DOI":"10.1089\/dia.2025.0075","article-title":"The effect of omnipod 5 automated insulin delivery on glycemic control in adolescents and adults with cystic fibrosis-related diabetes","author":"Scully","year":"2025","journal-title":"Diabetes Technology Ther"},{"issue":"1","key":"10.1016\/j.eprac.2026.05.038_bib55","doi-asserted-by":"crossref","first-page":"101","DOI":"10.2337\/dc23-1411","article-title":"Randomized trial of the insulin-only iLet bionic pancreas for the treatment of cystic Fibrosis\u2013 related diabetes","volume":"47","author":"Sherwood","year":"2024","journal-title":"Diabetes Care"},{"issue":"5","key":"10.1016\/j.eprac.2026.05.038_bib56","doi-asserted-by":"crossref","first-page":"1038","DOI":"10.1177\/193229681200600507","article-title":"Cystic fibrosis-related diabetes in adults: inpatient management of 121 patients during 410 admissions","volume":"6","author":"Rasouli","year":"2012","journal-title":"J Diabetes Sci Technol"},{"issue":"4","key":"10.1016\/j.eprac.2026.05.038_bib57","doi-asserted-by":"crossref","first-page":"732","DOI":"10.1016\/j.clnu.2014.08.016","article-title":"Carbohydrate intake and insulin requirement in children, adolescents and young adults with cystic fibrosis-related diabetes: a multicenter comparison to type 1 diabetes","volume":"34","author":"Scheuing","year":"2015","journal-title":"Clin Nutr"},{"issue":"7","key":"10.1016\/j.eprac.2026.05.038_bib58","doi-asserted-by":"crossref","first-page":"844","DOI":"10.1136\/gut.28.7.844","article-title":"Inhibition of the effect of serotonin on rat ileal transport by cisapride: evidence in favour of the involvement of 5-HT2 receptors","volume":"28","author":"Moriarty","year":"1987","journal-title":"Gut"},{"issue":"5","key":"10.1016\/j.eprac.2026.05.038_bib59","doi-asserted-by":"crossref","first-page":"469","DOI":"10.4158\/EP08331.RAR","article-title":"Glucocorticoid-induced hyperglycemia","volume":"15","author":"Clore","year":"2009","journal-title":"Endocr Pract"},{"issue":"4","key":"10.1016\/j.eprac.2026.05.038_bib60","first-page":"e112","article-title":"Canadian CFRD clinical practice survey: current screening and treatment patterns","volume":"47","author":"Ahmed","year":"2023","journal-title":"Can J Diabetes"},{"issue":"3","key":"10.1016\/j.eprac.2026.05.038_bib61","article-title":"Evolving non-insulin therapeutic strategies in adult CF clinics","volume":"41","author":"McKinney","year":"2024","journal-title":"Diabet Med"},{"key":"10.1016\/j.eprac.2026.05.038_bib62","article-title":"Practical aspects of diabetes technology use: continuous glucose monitors, insulin pumps, and automated insulin delivery systems","volume":"27","author":"Marks","year":"2022","journal-title":"J Clin Transl Endocrinol"},{"issue":"2","key":"10.1016\/j.eprac.2026.05.038_bib63","first-page":"244","article-title":"Adult CFRD management patterns across Europe","volume":"83","author":"Guillaume","year":"2025","journal-title":"Endocrine"},{"key":"10.1016\/j.eprac.2026.05.038_bib64","article-title":"Long-term sitagliptin therapy in CFRD: five-to-ten-year experience","volume":"34","author":"Nicholas","year":"2025","journal-title":"J Clin Transl Endocrinol"},{"key":"10.1016\/j.eprac.2026.05.038_bib65","article-title":"DPP-4 inhibitor therapy in adults with CFRD: single-center cohort","volume":"34","author":"Ahmed","year":"2025","journal-title":"J Clin Transl Endocrinol"},{"key":"10.1016\/j.eprac.2026.05.038_bib66","article-title":"DPP-4 inhibitors and glycemic variability in CFRD","volume":"16","author":"Roberts","year":"2025","journal-title":"Front Endocrinol (Lausanne)"},{"issue":"6","key":"10.1016\/j.eprac.2026.05.038_bib67","first-page":"e131","article-title":"GLP-1 receptor agonists for overweight CFRD patients: two-year series","volume":"22","author":"Beaulieu","year":"2023","journal-title":"J Cyst Fibros"},{"key":"10.1016\/j.eprac.2026.05.038_bib68","article-title":"GLP-1 receptor agonist therapy in CFRD complicated by obesity","volume":"38","author":"Nicholas","year":"2024","journal-title":"J Clin Transl Endocrinol"},{"issue":"6","key":"10.1016\/j.eprac.2026.05.038_bib69","first-page":"714","article-title":"GLP-1 receptor agonists in adult CF obesity: efficacy and safety","volume":"27","author":"Zhao","year":"2025","journal-title":"Diabetes Obes Metab"},{"issue":"2","key":"10.1016\/j.eprac.2026.05.038_bib70","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1089\/dia.2024.0367","article-title":"GLP-1 receptor agonist therapy in CFRD: case experience","volume":"27","author":"Liebert","year":"2025","journal-title":"Diabetes Technol Ther"},{"issue":"8","key":"10.1016\/j.eprac.2026.05.038_bib71","first-page":"2114","article-title":"Combined GLP-1 receptor agonist and CFTR modulator effects in CFRD","volume":"110","author":"Omari","year":"2025","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.eprac.2026.05.038_bib72","article-title":"GLP-1 receptor agonist therapy in CFRD complicated by obesity: updated 2025 series","volume":"41","author":"Ahmed","year":"2025","journal-title":"J Clin Transl Endocrinol"},{"key":"10.1016\/j.eprac.2026.05.038_bib73","article-title":"SGLT2 inhibitor therapy in overweight and Obese CFRD patients: twelve-month data","volume":"36","author":"Wong","year":"2025","journal-title":"J Clin Transl Endocrinol"},{"key":"10.1016\/j.eprac.2026.05.038_bib74","series-title":"Empagliflozin Pilot Trial for CFRD (Phase II)","author":"Pan","year":"2025"},{"key":"10.1016\/j.eprac.2026.05.038_bib75","article-title":"SGLT2 inhibitor therapy in overweight and Obese CFRD patients: case series","volume":"41","author":"Ahmed","year":"2025","journal-title":"J Clin Transl Endocrinol"},{"issue":"2","key":"10.1016\/j.eprac.2026.05.038_bib76","first-page":"311","article-title":"Pharmacokinetic modeling of metformin in adults with cystic fibrosis","volume":"118","author":"Tan","year":"2025","journal-title":"Clin Pharmacol Ther"},{"key":"10.1016\/j.eprac.2026.05.038_bib77","series-title":"Screening for Cystic Fibrosis-Related Diabetes: A Systematic Review","article-title":"Treatment of hyperglycaemia in cystic fibrosis","author":"Waugh","year":"2012"},{"issue":"10","key":"10.1016\/j.eprac.2026.05.038_bib78","doi-asserted-by":"crossref","first-page":"2438","DOI":"10.1016\/j.bbamem.2007.05.013","article-title":"CFTR inhibition by glibenclamide requires a positive charge in cytoplasmic loop three","volume":"1768","author":"Melin","year":"2007","journal-title":"Biochim Biophys Acta Biomembr"},{"issue":"5","key":"10.1016\/j.eprac.2026.05.038_bib79","article-title":"Drug treatments for cystic fibrosis\u2013related diabetes","volume":"2021","author":"Onady","year":"2021","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.eprac.2026.05.038_bib80","doi-asserted-by":"crossref","DOI":"10.1177\/17534666251317200","article-title":"New era, new goals: cardiovascular screening and lipid considerations in people with cystic fibrosis","volume":"19","author":"Despotes","year":"2025","journal-title":"Ther Adv Respir Dis"}],"container-title":["Endocrine Practice"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1530891X26010311?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1530891X26010311?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T21:49:11Z","timestamp":1790804951000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1530891X26010311"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10]]},"references-count":79,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2026,10]]}},"alternative-id":["S1530891X26010311"],"URL":"https:\/\/doi.org\/10.1016\/j.eprac.2026.05.038","relation":{},"ISSN":["1530-891X"],"issn-type":[{"value":"1530-891X","type":"print"}],"subject":[],"published":{"date-parts":[[2026,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Updates in Cystic Fibrosis\u2013Related Diabetes (CFRD)","name":"articletitle","label":"Article Title"},{"value":"Endocrine Practice","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.eprac.2026.05.038","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 AACE. Published by Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}